Monitor for any subsequent Form 4 filings by Thompson or OrbiMed affiliates, which would indicate actual trading activity. The conversion ratio and preferred holdings provide a baseline for future dilution tracking post-IPO.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 29 $14.89entry
- T+1 · 6d ago −12.42%α −11.95% · $13.04
- T+5 · due 11h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Peter A. Thompson filed a Form 3 initial statement of beneficial ownership with Aspen Neuroscience, disclosing indirect ownership of convertible preferred shares via OrbiMed Private Investments VII. The filing is a routine Section 16 compliance document with no trading activity or material corporate event.
Key Facts
- Form 3 filed by Peter A. Thompson as a reporting person for Aspen Neuroscience (ASPE).
- Thompson indirectly holds Series Seed-2, A-1, A-2, B, and C convertible preferred shares through OrbiMed Private Investments VII, LP.
- Preferred shares convert 1-for-9.8821 into common stock upon IPO completion; no expiration date.
- The filing includes a power of attorney appointing Jeffrey Boerneke as attorney-in-fact for Section 16 filings.
Financial Impact
No financial impact; the filing is a beneficial ownership disclosure with no transaction or change in position.
Risk Factors
- No material risks identified; this is a routine initial ownership filing.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-439049 |
| Document: 0001193125-26-439049-index-headers.html | 0001193125-26-439049 |
| Document: 0001193125-26-439049-index.html | 0001193125-26-439049 |
| Document: 0001193125-26-439049.txt | 0001193125-26-439049 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 2d ago | SC 13G | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Nov 2, 2026 2d ago | Insider Cluster | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Nov 2, 2026 2d ago | Insider Cluster | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Nov 2, 2026 3d ago | 8-K | $12.29 $12.76 | ▲ +3.82% | ▲ +2.17% | $11.76 (−4.31%) |
Oct 30, 2026 6d ago | 424B4 | $13.04 $12.29 | ▼ −5.75% | ▼ −6.05% | $11.76 (−9.82%) |
Oct 30, 2026 6d ago | EFFECT | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | Press Release | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | 3 | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | 3 | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
Oct 29, 2026 6d ago | 3 | $14.89 $13.04 | ▼ −12.42% | ▼ −11.95% | $11.76 (−21.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers